Last reviewed 2026-06-10 · How we verify

diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy — Treatment Landscape & Competitive Intelligence

diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Chimerix · 1 drug in diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy:

• diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy treatment updates — RSS
• diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy treatment updates — Atom
• diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy treatment updates — JSON

Cite this brief

Drug Landscape (2026). diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/diffuse-midline-glioma-harboring-an-h3-k27m-mutation-with-progressive-disease-following-prior-therapy. Accessed 2026-06-10.

Related

• diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing